Want to see SE:SUBGEN full AI Analyst Report?
SUBGEN Stock Chart & Stats
kr0.03
<kr0.01(6.67%)
―
--
Day’s Range― - ―
52-Week Rangekr0.03 - kr19.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)15.98M
Market Cap
kr72.42M
Enterprise Valuekr380.03M
Total Cash (Recent Filing)kr19.51M
Total Debt (Recent Filing)kr240.41M
Price to Earnings (P/E)―
Beta5.58
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.11
Shares Outstanding1,736,062,300
10 Day Avg. Volume16,419,437
30 Day Avg. Volume15,982,425
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)<0.01
Price to Sales (P/S)0.00073
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Revenue GrowthRevenue expansion of 90.7% indicates improving commercial traction and a growing operating base. If this growth persists, greater scale could help absorb fixed costs, support reinvestment in diagnostics products, and provide a foundation for eventual margin improvement.
Improved Operating Cash FlowThe return to positive operating cash flow is a constructive improvement in the company’s ability to generate cash from ongoing activities. Sustaining this progress would reduce reliance on external funding and provide greater flexibility to support commercialization and operations.
Positive Equity And Moderate LeveragePositive equity and moderate TTM leverage provide a more stable capital base than the company’s earlier periods of negative equity. This balance-sheet position may preserve some capacity to fund operations and pursue growth, provided losses and borrowing do not continue escalating.
Bears Say
Severe Operating LossesVery large operating and net losses show that current revenue scale is not yet covering the cost base. The widening net loss suggests expenses are rising faster than the business, creating a persistent need for funding and making durable profitability difficult to establish.
Negative Free Cash FlowNegative free cash flow means operating cash generation is still insufficient after investment requirements, despite improvement in operating cash flow. Continued shortfalls can constrain product development and commercialization, while increasing dependence on financing until profitability and cash conversion improve.
Sharp Increase In DebtThe sharp increase in debt raises financial pressure while returns remain negative, limiting the effectiveness of additional borrowing. Higher leverage can increase funding demands and reduce flexibility if losses persist, particularly after earlier periods of negative equity and balance-sheet volatility.
SUBGEN FAQ
What was AegirBio AB’s price range in the past 12 months?
AegirBio AB lowest stock price was kr0.03 and its highest was kr19.68 in the past 12 months.
What is AegirBio AB’s market cap?
AegirBio AB’s market cap is kr72.42M.
When is AegirBio AB’s upcoming earnings report date?
AegirBio AB’s upcoming earnings report date is Nov 05, 2026 which is in 5 days.
How were AegirBio AB’s earnings last quarter?
AegirBio AB released its earnings results on Aug 20, 2026. The company reported -kr0.015 earnings per share for the quarter.
Is AegirBio AB overvalued?
According to Wall Street analysts AegirBio AB’s price is currently Undervalued.
Does AegirBio AB pay dividends?
AegirBio AB does not currently pay dividends.
What is AegirBio AB’s EPS estimate?
AegirBio AB’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does AegirBio AB have?
AegirBio AB has 1,736,062,300 shares outstanding.
What happened to AegirBio AB’s price movement after its last earnings report?
AegirBio AB reported an EPS of -kr0.015 in its last earnings report. Following the earnings report the stock price went down -11.538%.
Which hedge fund is a major shareholder of AegirBio AB?
Currently, no hedge funds are holding shares in SE:SUBGEN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
AegirBio AB
Subgen AI AB develops artificial intelligence-based models and applications to control data for government and businesses. The company engages in the provision of information society services aimed at delivering financial and related knowledge tools to facilitate third-party access to financial literacy and instruments that enable them to interpret such information through e-learning; the acquisition, ownership, management and administration of securities; and the acquisition, ownership, marketing, leasing and operation of rural or urban properties. It also provides financial intermediation services; computer programming activities, structure and content design, writes computer code for systems, computer software, databases and web pages; and customizes computer programs, including configuration and modification of legacy programs. In addition, the company offers marketing and after-sales services of diagnostic imaging machinery and human resources services, as well as development of state-of-the-art artificial intelligence (Al) systems. Further, it provides Serenity Star, AI4D core, and Substrate Cloud. The company is based in London, United Kingdom. Subgen AI AB operates as a subsidiary of Substrate Artificial Inteligence, S.A.